1-1 of 1
Nicola D. Roberts
Close
Sort by
Journal Articles

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Clinical Trials & Observations
Susan Branford, David T. Yeung, Wendy T. Parker, Nicola D. Roberts, Leanne Purins, Jodi A. Braley, Haley K. Altamura, Alexandra L. Yeoman, Jasmina Georgievski, Bronte A. Jamison, Stuart Phillis, Zoe Donaldson, Mary Leong, Linda Fletcher, John F. Seymour, Andrew P. Grigg, David M. Ross, Timothy P. Hughes
Journal: Blood
Blood (2014) 124 (4): 511–518.
https://doi.org/10.1182/blood-2014-03-566323
Published: 2014
Includes: Supplemental data